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ABSTRACT
Introduction: Rotavirus (RV) vaccination was
introduced in Belgium in 2006. With the high
uptake it had ([85%), a sharp decline in
hospitalizations was observed during the first
years after vaccine introduction. The objective
of this study was to investigate whether this
decline was maintained and to simulate
projections.
Methods: The Rotavirus Belgium Impact Study
allowed an analysis of the RV vaccine impact
amongst children in 11 hospitals in Belgium
over a 9-year period (2005–2013) with 2 years
pre- and 7 years post-vaccine introduction.
Results were compared by year and by
subsequent birth cohort aging up to 5 years.
The two different analysis methods helped
dismantling the different (direct and indirect)
effects of vaccine protection to simulate future
hospitalization trends.
Results: During the whole observation period,
40,552 RV detection tests were performed of
which 5832 were positive (14.4%). After RV
vaccine introduction, a significant reduction in
number of tests performed (-38%) was
combined with a dramatic drop in numbers of
positive tests (-76.6%). The decreases were
spectacular during the first two years of
vaccine introduction; after that period, the
decrease flattened. Cross-sectional comparison
with cohort data showed that the initial drop
was heavily influenced by the herd effect of the
vaccine. Cohort analysis demonstrated a low
rate of residual disease over time, suggesting
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another infection source other than the child
population.
Conclusion: The residual disease will be
maintained in the community when a same
vaccination strategy is continued over time,
starting vaccination of children only at 6 weeks’
time.
Funding: GlaxoSmithKline Biologicals SA.





Rotavirus (RV) infection is one of the most
common causes of diarrhea in young children
less than 5 years old across the world, before the
vaccine introduction in 2006 [1, 2]. The
infection is normally endemic but shows a
higher frequency among young children
during the winter period, especially in the
more temperate climates of the developed
world [3–5]. Severe consequences of RV
gastroenteritis (RVGE) are more often observed
in children under the age of 2 years, after which
a dramatic drop in the number of diarrhea
events is noticed [6]. After 5 years of age,
children have normally acquired a natural
immunity so that RV diarrhea is seldom
reported [7–9].
RVGE is very contagious and its spread
therefore remains difficult to control, even
with rigorous application of primary hygienic
measures [10]. As a result, the RVGE peaks are
well-known as annually recurring public health
problems. In Belgium for instance, before the
introduction of the RV vaccine, the disease was
causing a burden of around 70,000–75,000
diarrhea events per year (community-acquired
and hospitalizations) in children under the age
of 7 years [11, 12]. The RV infection has some
interesting features that make the contagion
quite unique. Indeed, RV immunity is built up
by successive infection exposures of which the
first one is the most severe leading to acute
symptoms but the following ones are
progressively less severe [9, 13].
To reduce this public health burden, a radical
change in disease prevention should be
considered such as the early stimulation of
infants’ immunity between the ages of 6 and
10 weeks, thus providing protection before a
first infection after which repeated exposures
may assess a natural boost to immunity. This
new prevention strategy can use RV vaccines
available in Europe: a two-dose vaccine
available since 2006, RotarixTM (GSK), and a
three-dose vaccine available since 2007, Rotateq
(Merck and Co. Inc.). The first dose of the
vaccine can be administered from 6 weeks of
age, with a minimum interval of 4 weeks
between subsequent doses [14, 15]. Although
vaccination is recommended by European
guidelines [16] and by the World Health
Organization [17, 18], only 4 countries in
Western Europe introduced the RV vaccine
into their routine immunization schedules
soon after the vaccine became available:
Austria, Belgium, Finland, and Luxemburg
[19]. By February 2014, national universal RV
vaccination recommendations had been
implemented in a few additional countries,
including Estonia, Germany, Norway, and the
United Kingdom (UK) [20].
Studies from Austria [21, 22], Finland [20,
23], and Belgium [24–26] have reported quite
impressive reductions in hospitalizations
2–3 years after vaccine introduction combined
with a vaccine herd effect. The medium- to
long-term effect of the vaccine within the same
at-risk group has not often been reported [27,
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28]. In the current study, we report about results
of Belgium where the vaccine uptake was very
high from start ([85% in the first year) and
where cohorts of children B5 years of age were
followed from 2005 through 2013 (2 years
pre-vaccination and 7 years post-vaccination)
[29]. Such a long follow-up period should help
in better understanding how the vaccine is
working in real-life conditions. Hypothesizing
that there is only one infection source (the
children themselves) and that the vaccine
effectiveness remains the same together with a
well-maintained high vaccine uptake ([85%),
the RVGE hospitalization rate should decrease
year after year, potentially leading to an
elimination of the very severe disease cases
very soon as disease modelers were speculating
[30]. The present study aims to verify this
hypothesis by analyzing and comparing the
annual number of hospitalizations observed
versus the expected ones through an
appropriate modeling exercise in several birth
cohorts over time. If major deviations between
model-expected and observed results exist, the
shape of the curve could help identifying a
likely reason for the difference. Sources of curve
deviation could include another source of
infection not affected by the vaccine, vaccine
waning, variable vaccine coverage rate,
selection bias among some of the participating




Retrospective hospital database analyses
were conducted (ClinicalTrials.gov identifier,
NCT01563146) over an observation period of
9 years (2005–2013), at the same 11 hospitals in
Belgium: 9 were general hospitals with a
pediatric ward; 2 were pediatric-only hospitals.
Among the 11 centers, 4 were university
hospitals. The centers were distributed across
the country and covered the three regions of
Brussels, Flanders, and Wallonia. All of the
centers combined had around 500 pediatric
beds, representing 17% of the total of 2750
pediatric beds in Belgium.
Each participating center provided
information on the laboratory assays used to
detect RV. In each center, the following
information were collected: Center code;
children’s date of birth; children’s age; gender;
date of sampling; RV tests (negative, positive);
outcome (ambulatory or hospitalized); date of
hospital admission and discharge; and length
of hospital stay in days. The data were
anonymized before any analysis occurred. All
procedures followed were in accordance with
the ethical standards of the responsible
committee in each center. The approval for
the study was obtained from each center and for
each year the data were collected.
All children under 6 years of age who had an
RV detection test performed at one of the
participating centers from January 1, 2005 to
May 31, 2013 were eligible for inclusion in the
current analysis. The pre-vaccination study
period was defined as from January 1, 2005 to
December 31, 2006. The period from January 1,
2007 to May 31, 2013 was considered as the
post-vaccination period (reimbursement of the
vaccine was introduced in November 2006). The
number of tests performed and the proportion
of RV-positive tests were calculated for each
participating center, per month, per year and
for 7 different age-groups (B2 months,
[2–12 months, [12 months–2 years, [2–3
years, [3–4 years, [4–5 years, [5 years).
Children aged \12 months were subdivided
into two groups (B2 months and
[2–12 months) because the former group was
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too young for vaccination but could experience
a herd protection effect once the vaccine is
introduced.
Data Analysis
The data were analyzed in two different ways:
• Cross-sectional analysis The number of
hospitalizations during the yearly peak
periods (January until the end of May) for
the 7 age-groups during the period
2005–2013 was summed up and reported
annually. The data were compared by
age-group and overall per year:
pre-vaccination versus post-vaccination (1st
year, 2nd year, nth year, …, 7th year post-
vaccination).
• Birth cohort analysis The number of
hospitalizations during the peak period was
noted in the birth cohort for the 1st and for
each subsequent year of that cohort until the
children were getting 5 years old. The results
were summed up by year for each birth
cohort and for the total follow-up period.
The results were compared by subsequent
birth cohorts. Using this approach, we could
report 3 vaccinated subsequent birth cohorts
getting 5 years old and 5 vaccinated
subsequent birth cohorts getting 3 years
old. We also compared those results with
the pre-vaccination period but
cross-sectional only as those data were not
under the influence of RV vaccination.
Two important assumptions underlying the
comparison of the annual number of
RV-positive tests were that the catchment area
for each of the participating centers remained
the same across the whole observation period of
9 years and that no change in disease
management behavior for testing the children
B5 years old on RV disease occurred during that
period. It means that if fewer tests were
performed once the vaccine has been
introduced, this has mainly to do with less
suspected cases presenting themselves to the
hospital unit and not with a change in behavior
of the physician who was less likely to perform
RV tests once the vaccine was introduced.
Therefore, the most relevant value to compare
between the years is the accumulated number of
RV-positive tests and not the proportion of
RV-positive tests.
Model Simulation
To well-understand the real impact the vaccine
has, this can best be achieved by comparing
observed results with a model simulation in
which we separately control the different
aspects that could impact on the outcome
(hospital reduction) such as changing the
vaccine efficacy (VE) over time, initiating a
second source of infection not being affected by
the vaccine, changing the vaccine waning rate,
or changing the vaccine uptake per year. For
doing that comparison we selected from the
observed data the birth cohort follow-up data
up to the age of 3 years to obtain enough
data-points over time.
A time difference equation model was
developed based on the initial data collection
of the first years of observation. An analysis was
then simulated in which the decrease in
hospital numbers for the first few years fitted
the observed data with fixed parameters over
time, a calibration process:
xtþ1 ¼ gx0 þ 1 gð Þ 1 qrtxt
 
xt
in which: xt is the number of hospitalizations in
year t; xr is the residual number of
hospitalizations such that xr ¼ gx0 where g is
the fraction of hospitalizations caused by
another source of infection; q is a fixed
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parameter equivalent to the VE; rt is the vaccine
coverage rate in year t; x is a fixed parameter
reflecting VE waning over time; and t is the time
indicator expressed in year units.
With this model, we may easily adjust the
shape of the simulated curve changing
separately q or the VE, the vaccine uptake (rt)
at specific t time points, the vaccine waning by
decreasing x, and the residual disease caused by
another source of infection by changing g. The
simulated shape can then be compared with the
observed data and the best fit is selected for the
most plausible scenario of projected future
hospitalizations related to the disease. No
statistically significant difference between the
curves were tested using Mann–Whitney
U testing (P\0.05) and by calculating R2 value
(Stata 11.2; StataCorp LP, College Station, TX,
USA).
Outcomes
An annual comparison of cross-sectional data
will identify the importance of the herd effect
generated by the vaccine. Analyzing and
comparing successively vaccinated birth
cohorts over time will indicate whether the
vaccine wanes. Comparison of the summary
measures of vaccinated birth cohorts per year
with simulated predictions will test the
hypothesis about different sources of infection.
Finally, the proportional difference in
RV-positive tests between pre- versus the most
recent post-vaccination period analyzed
(2012–2013) across the 11 participating centers
will identify any selection bias in participating
centers that may explain why residual disease
could be observed over time. Results are tested
for statistical significance using Chi-square tests
(using Stata 11.2) for trend of proportional data,




Among the 11 participating centers, 40,552
RV tests were conducted over the observation
period of 9 years, with a much higher
frequency during the peak months. The
overall number of RV-positive tests recorded
during that period was 5832 (14.4%). Over the
years, the overall number of tests performed
significantly decreased from 6278 tests in 2006
during the pre-vaccination period to 3893
tests in 2012 during the post-vaccination
period, representing a reduction of 38%.
Moreover, the absolute number of
RV-positive tests decreased from 1399 tests in
2006 during the pre-vaccination period to 327
tests in 2012 during the post-vaccination
period, representing a reduction of 76.6%.
The decrease in RV-positive tests was
extremely sharp during the first 2–3 years
after the introduction of the vaccine and
then flattened over time, compared with the
more linear decrease in the number of
RV-negative tests over time (Fig. 1).
Fig. 1 Number of RV-negative and RV-positive tests
performed per year in the 11 participating centers Nbr
number, RV rotavirus
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The non-linear reduction in the number of
RV-positive tests over time was statistically
significant (v2 = 215.95; P\0.0001).
The number of RV-positive tests is shown by
age-group and year in Fig. 2. There was a sharp
drop in the number of RV-positive cases in the
first year after the introductionof RVvaccination,
especially in the vaccinated age-groups
([2–12 months and[12months–2 years) which
represent nearly 78% of the entire study
population. There was also a drop in the number
of positive cases in children who were either too
young (B2 months) or too old ([6 months) to be
immunized.
Birth Cohort Analysis
Table 1 shows the numbers of RV-positive tests
by age-group and by year for each peak period
(January until end of May). The accumulated
data represent 85% of the total RV-positive
tests, with the remaining 15% observed in the
other months of the year, especially November
and December.
In 2007, the cross-sectional results indicated
a total of 710 RV-positive tests, which was 44%
lower than the year before when no vaccine was
provided (there were 1271 RV-positive tests
in 2006). By following the birth cohort
from 2007 to 2012, and summing the values
year-by-year with increasing age in the
Table (69 ? 305 ? 199 ? 44 ? 16 ? 5 ? 2), 640
RV-positive tests are reached. As expected, this
is lower than the cross-sectional result of 2007.
There is a difference between the two values
(710 versus 640) caused by the herd effect only
(marked as yellow cells in the table for the
cross-sectional calculation) versus the
age-groups subject to direct vaccine effect plus
the herd effect (marked as light brown cohort
cells; Table 1).
A herd effect was maintained after the first
5 years of the vaccination program, as shown by
the continued reduction in RV-positive tests
seen in children\2 months of age who are too
young for vaccination (first row, yellow cells;
Table 1).
A particularly interesting finding in the
cohort analysis is that the data do not
show any significant additional drop in
the early age-groups ([2–12 months and
12 months–2 years) after the large decrease of
the first 2 years. This indicates that the rate of
decrease in hospitalization changes over time,
which indirectly reveals that another factor
must influence the process of RV infection in
this child population.
Model Simulations
Figure 3 compares first-year observed results
(Fig. 3a) with simulations of having another
source of infection in the population (Fig. 3b),
having no other source of infection in the
population (Fig. 3c), vaccine waning (Fig. 3d),
and having a different vaccine uptake scenario
(Fig. 3e).
There is a good fit between the observed data
and the simulations for the first 3 years when
the q-factor in the simulation equation equals
0.5 and no other source of infection was present
Fig. 2 Distribution of RV-positive tests by age-group and
year. Nbr number, RV rotavirus, mo months, yrs years
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(Fig. 3c). Under such scenario we could normally
foresee an elimination of the disease over a few
years as it was hypothesized by some modelers.
However, a much better overall good fit of the
whole observed curve shape (Fig. 3b) was
obtained if the additional source of infection
with residual disease (g-factor) was introduced in
addition to the q-factor. The g-factor was
estimated at 12% of the hospitalizations in
the equation (R2 = 0.989; Mann–Whitney
U rank-sum test between observed and
simulated curve, z stat= 0.368, P = 0.713).
For vaccine waning (Fig. 3d), we first
simulated a decrease of 10% of x per year. To
obtain a perfect fit with the observed data the
annual waning would have to reach 35%,
starting in the second year of vaccination.
Varying the vaccine uptake from 85% to 65%
in the 3rd year doesn’t affect the curve (Fig. 3e)
so much as the biggest drop in hospitalization
occurs in the first years and what happens
thereafter appears having a marginal effect. The
point to make here is that any decrease in
vaccine uptake later on, cannot explain the
observed curve as it is now.
Finally the proportion of RV-positive tests
across all the participating hospital centers was
higher during the pre-vaccination period
(2005–2006) than during the post-vaccination
period (2012–2013) as expected. The average
difference between 2005–2006 and each of 2012
and 2013 was 0.163 (minimum 0.10 to
maximum 0.24) and 0.178 (minimum 0.07 to
maximum 0.30), respectively. No center was
noticeably an outlier (see Fig. 4).
DISCUSSION
This analysis of medium- to long-term impact of
RV vaccination on specific tests measured
annually in the same 11 hospital centers in
Belgium has identified several interesting
features.
First, there is a large reduction in frequency
of RV disease during the normal seasonal peak
period after vaccination of the first birth cohort
had started. The decrease of 70–80% in
RV-positive tests, compared with the period of
no vaccination, is achieved within 2 years after
vaccine introduction. These findings have




Year/Age 2005 2006 2007 2008 2009 2010 2011 2012 2013 Total 
2 months 84 100 69 45 41 32 44 31 28 474 
>2–12 months 551 634 305 127 108 101 95 80 82 2083 
>12 months–2 years 367 381 266 199 88 116 107 88 89 1701 
>2–3 years 82 111 51 59 44 23 38 29 31 468 
>3–4 years 16 34 14 18 16 16 7 9 13 143 
>4–5 years 9 10 3 12 7 7 5 5 3 61 
>5 years 2 1 2 1 0 6 10 2 7 31 
Total CS 1111 1271 710 461 304 301 306 244 253 4961 
Total BC 640 302
Brown cells: vaccine effect evaluated by cohort; yellow cells: herd protection only; white cells: no vaccine effect. Colored bold
numbers (red and dark brown) indicate how the BC totals are calculated per follow-up until the BC reaches 5 years. Only
two BCs (2007 and 2008) have reached the full 5 year follow-up period under the vaccine effect. Comparing the full-vaccine
effect has a bigger impact by BC than CS by year up to the age of 5 years (710 CS versus 640 BC 1st evaluation and 461 CS
versus 302 BC 2nd evaluation)
BC birth cohort, CS cross-sectional
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already been reported in previous publications
for Belgium [25, 32]. After that large initial drop
however, subsequent annual decreases are more
modest (around 10–15% per age-group). A
similar early vaccine effect (the sharp drop in
the first year) has been observed in the UK
during the first year after the vaccine
introduction [33]. The decline is more
spectacular during the first year than in the
present study. This could be due to the start
date of the vaccination campaign in the UK,
which was planned by the end of the second
quarter the year before the start of the next peak
season. In Belgium, vaccination began much
closer to the next peak season, namely in the
fourth quarter of the year [34].
Second, in addition to the important direct
vaccine effect seen in the first vaccinated birth
cohort, we also observe, during the same period,
a substantial drop in the unvaccinated
age-groups (i.e., children too young or too old
to be vaccinated, as shown in Table 1). This
phenomenon clearly indicates the high
transmission rate of the virus between the
Fig. 3 Comparing observed data (a) with simulations of
adding residual disease over time (b); with ﬁxed reduction
in RV-positive tests without residual disease (c); vaccine
waning (-10% per year) (d); changing vaccine coverage
rate (85% to 65%) (e). Nbr number, RV rotavirus
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different age-groups, resulting in a high indirect
herd protection effect of the vaccine during the
first years of the vaccination program until the
whole at-risk group (aged up to 5 years old) is
covered. The herd protection during the first
and second year after the vaccine introduction
is estimated at 40% (233/561) and 15% (123/
810), respectively, relative to the overall
reduction in hospital events per year as
compared to the baseline values of 2006.
The overall drop in disease events was
spectacular during the first two years, because
the younger age-groups targeted by the vaccine
program are the groups most affected by RV
disease (peak incidence rates) and are the
highest receivers and transmitters of the virus
to other age-groups. Virus transmission within
these age-groups and to other age-groups was
directly and indirectly reduced by the vaccine.
Once the at-risk group has been vaccinated,
herd protection in the older age-groups would
be expected to disappear, as children in this
group would have been vaccinated when they
were younger. This would leave the herd effect
being present only in children B2 months of
age (who are too young for vaccination) as an
additional benefit sustained over time.
With 7 years of real-world observations after
vaccine introduction, this study provides
information about the likely source of
infection of RV disease in the child population.
The results split by age-group in Fig. 2 indicate
that the role of the vaccine is primarily to stop
the spread of the infection within the child
population. The vaccine fulfills that task very
well, as it induces a high level of herd protection
across the different unvaccinated age-groups
during the same period. To obtain such a high
Fig. 4 Difference in proportion of RV-positive tests during the post-vaccination period (2012 and 2013) compared with
the pre-vaccination period (2006) in each hospital center (code). RV rotavirus
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vaccine impact, the main source of infection
must be within the children themselves as it
blocks the root cause of infection transmission.
However, the amount of indirect effect depends
heavily on how children are normally nurtured
during that period. For example, do they attend
day-care centers and at what starting age, do
they have regular contact with other children
elsewhere, and are different disease patterns
observed between different age-groups if child
management or behavior changes? These
questions affect the likely sources of infection
and patterns of disease transmission between
and within age-groups, and would be valuable
areas for further research. Finally, the different
observed rates of disease reduction in
subsequent years across different age-groups
are a signal that different infection forces
operate within the child population. The most
plausible explanation, simulated in Fig. 3, is that
there are additional sources of infection that are
seen once most of the herd effect has faded away
after the RV-vaccine program has been in place
for a few years and all the at-risk children have
been vaccinated. This scenario appears much
more likely than a vaccine waning scenario,
because an annual decrease of 35% in vaccine
effect starting 1 year after its introduction must
occur to fit the observed data. Another
possibility could be that the vaccination
coverage rate fluctuated over time, but it is
unlikely that that potential disturbance may
impact so heavily the outcome results. In
addition, the vaccine coverage rate in Belgium
remained stable and quite high during the
whole observation period ([86%, [32]).
These indications of additional sources of
infection suggest that the disease and the virus
will not be easily eliminated unless the other
sources of infection can be targeted by different
vaccination strategies.
A cohort analysis illustrates effects within
the child population over time, including the
dynamics of indirect vaccine impact. This type
of investigation is more sensitive and better able
to identify the real-world benefit of the vaccine
than using VE data obtained through
randomized clinical trials, where the control
group may be influenced by the herd
protection. This may reduce the measured VE,
as seen in the European trial [35].
Following a first birth cohort over time
should normally demonstrate a larger
reduction of RV-positive tests than a first-year
cross-sectional evaluation, because the
vaccinated birth cohort includes a mixture of
direct and indirect vaccine effects in each
subsequent year if the coverage rate is not
100%. In contrast, the cross-sectional analysis
only includes the measured herd effect in
addition to the first-year direct effect of
vaccination of a small age-group. Thus, we
would expect to observe a larger effect in the
birth cohort analysis than the cross-sectional
analysis when comparing the two datasets,
which is consistent with what is observed in
this study. However, cross-sectional and cohort
data would be expected to reach the same end
result for the sum of the different at-risk
age-groups as soon as all the children from all
the different at-risk age-groups have been
vaccinated, approximately 10 years from the
start [36, 37]. Comparing birth cohort and
cross-sectional analyses can also allow
estimating the magnitude of the pure herd
effect that can be generated by the vaccine in
this disease.
Finally, all centers responded to the vaccine
in a similar way over time. The observation of a
residual disease burden could have been linked
to specific centers that did not apply the same
vaccination strategy in their catchment area, or
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to potential insourcing in some specific areas of
unvaccinated children from outside Belgium
where vaccination is not yet routinely
performed. These possibilities were not
measured in the present study.
A limitation of the current study is that we
do not fully control the denominator of the
study, and thus we assume that the target
population has not significantly changed over
the 9 years of the study period. For a small
country like Belgium, with a stable population
(the birth cohort may change by less than 0.6%
per year), this assumption is reasonable.
Another assumption is that no change
behavior in testing the children for RV
infection appeared over time after the
introduction of the vaccine.
CONCLUSIONS
The analysis here presented may provide the
evidence for another source of RV infection
after the introduction of the RV-vaccine that
exists outside the child population such as
care-givers at home or day-care centers, even
the animal environment. This source appears to
be less spectacular in spreading the disease in
the child population than the transmission
within the age-group. It may also less likely be
significantly influenced by vaccination because
the current strategy may not directly touch
these reservoirs.
The results of this study help to fill an
information gap about the impact of RV
vaccination over the medium- to long-term.
The main features reported are the sustained
reduction in hospitalization. The new finding
about different sources of infection in the child
population reveals that it may be difficult to
reduce the disease to very low levels. A residual
disease presence observed over time means that
we need to continue to monitor the events each
year to detect any new developments.
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